![h3 biomedicine h3 biomedicine](https://s18282.pcdn.co/wp-content/uploads/2020/05/5-0_Careers_H3Bio_8707_HiRes.jpg)
10 Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Elm and Carlton Streets, Buffalo, New York, 14263, USA.
![h3 biomedicine h3 biomedicine](https://pbs.twimg.com/media/CPgduIQWwAAXO0_.png)
8 H3 Biomedicine, Inc., 300 Technology Square, Cambridge, Massachusetts, 02139, USA.7 Key Laboratory of Agricultural Animal Genetics, Breeding and Reproduction of the Ministry of Education, College of Animal Science and Technology, Huazhong Agricultural University, Wuhan, 430070, China.6 Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Smithville, 78957, Texas, USA.5 Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Elm and Carlton Streets, Buffalo, New York, 14263, USA.4 Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, 14263, New York, USA. 3 Key Laboratory of Agricultural Animal Genetics, Breeding and Reproduction of the Ministry of Education, College of Animal Science and Technology, Huazhong Agricultural University, Wuhan, 430070, China. 2 College of Biology, Hunan University, Changsha, 410082, China. 1 Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Elm and Carlton Streets, Buffalo, New York, 14263, USA.Uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics, H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. H3 Biomedicine Inc., the U.S.-based precision oncology research and development subsidiary of Eisai Co., Ltd., is solely focused on advancing drugs from bench to bedside.
![h3 biomedicine h3 biomedicine](https://www.kisacoresearch.com/sites/default/files/styles/panopoly_image_square/public/speakers/use_this_headshot_please_tasuku.jpg)
"I am excited to join H3’s Board and help contribute to the company’s mission of advancing personalized medicines to better treat breast cancer, hepatocellular carcinoma and other advanced solid tumors." "H3’s innovative and data-driven approach to precision oncology research has the potential to bring much needed therapies to patients with cancer," said Dr. Woodman served as Senior Medical Director at Johnson & Johnson, where he led the oncology/hematology franchise at Ortho Biotech Products, LP. Oncology Clinical Development and Medical Affairs after his initial position of Franchise Head for Hematology in Global Medical Affairs. Woodman spent 12 years at Novartis, where he served as Head of U.S.
Before Eisai, he served as Chief Medical Officer and Head of Research and Development at Onconova Therapeutics.
#H3 biomedicine trial#
Woodman currently serves as Chief Clinical Officer (CCLO) of Eisai’s Oncology Business Group where he is responsible for overseeing the development of the company’s next generation oncology products, including management of design protocols, implementation of clinical trials and interpretation of trial results in preparation for applications to global regulatory authorities. Woodman has already made significant contributions since joining Eisai almost one year ago and we are delighted to welcome him to our Board."ĭr. Takashi Owa, Ph.D., Chairman and Chief Executive Officer of H3. His insights and guidance will be invaluable to the future growth of the company as we continue the research and development of our potential precision medicine treatments for patients with cancer," said Dr. Woodman brings extensive industry and clinical knowledge to H3. "With over 18 years of oncology-focused pharmaceutical experience at both large and small biotechnology organizations and his years in academia, Dr. (H3), a U.S.-based precision medicine research & development subsidiary of Eisai Co., Ltd., today announced the addition of Richard Woodman, M.D. CAMBRIDGE, Mass., January 10, 2022-( BUSINESS WIRE)- H3 Biomedicine Inc.